Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.5900 $TBUFF
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
Marketwired - Thu Jan 29, 3:14PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced that it has retained BND Projects Inc. ("BND" to provide it with investor relations services. The services to be provided by BND include (i) introducing the Company to the Canadian investment community, (ii) updating the investor base on a regular basis about the Company's fundamentals and goals and milestones, (iii) organizing investor road shows for the Company's management and (iv) assisting with the preparation of corporate communications and presentations.
TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
Marketwired - Tue Jan 27, 7:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today provided an interim update on its anticipated fourth quarter performance and total fiscal 2014 performance as follows:
TRX.VN: 0.730 (-0.010)
Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:29AM CST
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST
Tribute Pharmaceuticals to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
MILTON, ON / ACCESSWIRE / November 7, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TRX.V) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 11:00 AM Eastern Time.
Tribute Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:47PM CST
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 10:49AM CST
This release corrects and replaces the press release sent on November 3 at 10:26 AM ET for Tribute Pharmaceuticals Canada Inc. In the first paragraph, "second quarter ending September 30, 2014" has been changed to "third quarter ending September 30, 2014". The corrected version follows.
TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 9:26AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, November 10, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending September 30, 2014.
TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe
Marketwired - Thu Oct 30, 7:41AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , today announced that it has received a patent approval from the European Patent Office ("EPO" for intellectual property central to one of the Company's lead products, Uracyst(R)/Uropol(R) (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG" deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation- induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulfate in an amount of at least 400 mgs and an aqueous vehicle. This patent will run until February 18, 2024.
TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R)
Marketwire - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide®
Marketwire Canada - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company" , is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.46 (+0.01), TRIL: 13.25 (-0.75)
Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
Marketwired - Thu Jan 29, 3:14PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced that it has retained BND Projects Inc. ("BND" to provide it with investor relations services. The services to be provided by BND include (i) introducing the Company to the Canadian investment community, (ii) updating the investor base on a regular basis about the Company's fundamentals and goals and milestones, (iii) organizing investor road shows for the Company's management and (iv) assisting with the preparation of corporate communications and presentations. TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
Marketwired - Tue Jan 27, 7:31AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today provided an interim update on its anticipated fourth quarter performance and total fiscal 2014 performance as follows: TRX.VN: 0.730 (-0.010)
Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:29AM CST
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST
Tribute Pharmaceuticals to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
MILTON, ON / ACCESSWIRE / November 7, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TRX.V) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 11:00 AM Eastern Time.
Tribute Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:47PM CST
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 10:49AM CST
This release corrects and replaces the press release sent on November 3 at 10:26 AM ET for Tribute Pharmaceuticals Canada Inc. In the first paragraph, "second quarter ending September 30, 2014" has been changed to "third quarter ending September 30, 2014". The corrected version follows.
TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 9:26AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, November 10, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending September 30, 2014. TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe
Marketwired - Thu Oct 30, 7:41AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, today announced that it has received a patent approval from the European Patent Office ("EPO" for intellectual property central to one of the Company's lead products, Uracyst(R)/Uropol(R) (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG" deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation- induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulfate in an amount of at least 400 mgs and an aqueous vehicle. This patent will run until February 18, 2024. TRX.VN: 0.730 (-0.010)
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R)
Marketwire - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million. TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide®
Marketwire Canada - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"
, is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million. TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
